Physician profile
Michael Wayne Schriver
NPI 1104322536
$8,910.26
in general payments reported to CMS, 2019-2025
45 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.93 · 2020: $268 · 2021: $1,369 · 2022: $2,897 · 2023: $1,837 · 2024: $1,465 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,361.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.42 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,274.78 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $589.77 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $566.43 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $544.34 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $540.94 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $513.44 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.30 | 2021-2025 | Jardiance |
| Insulet Corporation | $326.38 | 2020-2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $199.48 | 2021-2025 | |
| Pfizer INC. | $173.89 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $169.80 | 2021-2024 | |
| Edwards Lifesciences Corporation | $168.40 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $160.36 | 2021-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $130.95 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schriver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.